Abstract YO27
Case summary
Whole Brain Radiotherapy plays a pivoted role in brain metastases. There is controversy regarding the radiotherapeutics dose fractionation in brain metastasis. 30 Gray in 10 fractions in 2 weeks in the standard regimen in most centers. Regarding the extraordinary poor survival prognosis of patients with brain metastasis, 20 Gray in 5 fractions over 1 week would be preferable. An observational comparative analytical study was conducted in National Academy of Medical Sciences (NAMS) Bir Hospital after ethical approval from the institutional review board of NAMS. Patients were randomized into two group one with 20 Gray in 5 fraction over one week and other with the 30Gray in 10 Fraction over 2 weeks. A total number of 55 patients were enrolled in the study. Assessment of clinical symptoms was done using Common terminology Criteria for Adverse Events (CTCAE), before treatment, just after treatment and 6 weeks of treatment. Response evaluation criteria in solid tumors (RECIST) was used to access the treatment response in terms of local control. Acute toxicity of the patients were assess during treatment and then followed for 6 weeks and graded according to Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring. Of the 55 patients enrolled, in 20Gray/5# (n=28) and 30Gray/10# (n=26) groups, all participants in the study received the planned treatment of radiotherapy. Local control with complete or partial response was 63% in 20Gray v 48% in 30Gray (p = 0.722). Six month survival was 29.1% in 20Gray/5# v 23.6% in 30Gray/10# (p = 0.504). Objective Responsive of Headache was 53% v 52% (p= 0.469), vomiting 43% v 55%,(p=0.956),Seizure 11.7% v 3.7% (p = 0.979), focal weakness 21.3% v 4.4% (p=0.249), ataxia1 4.3% v 3.7% (p=0.281), speech disorder 3.5% v 7.4% (p=0.147), acute toxicities of grade 2 and grade 3 were acceptable in both Groups, nausea 9.1% v 9.1% ( p =0.907), vomiting 1.9% v 3.7% (p=0.199) , headache 1.9% v 3.7% (p=0.696) and Dermatitis 5.7% v 5.7% (p =0.140) 20Gray in 5fractions and 30Gray in 10 Fractions are equally effective and feasible as statistically insignificant difference in the response rate and acute toxicities were observed in the two groups
Clinical trial identification
Editorial acknowledgement
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract